Abstract
BackgroundWe performed this study to explore the prognostic value of the pretreatment aspartate transaminase to alanine transaminase (De Ritis) ratio in patients with renal cell carcinoma (RCC).MethodsPubMed, EMBASE, Web of Science, and Cochrane Library were searched to identify all studies. The hazard ratio (HR) with a 95% confidence interval (CI) for overall survival (OS) and cancer-specific survival (CSS) were extracted to evaluate their correlation.ResultsA total of 6,528 patients from 11 studies were included in the pooled analysis. Patients with a higher pretreatment De Ritis ratio had worse OS (HR = 1.41, p < 0.001) and CSS (HR = 1.59, p < 0.001). Subgroup analysis according to ethnicity, disease stage, cutoff value, and sample size revealed that the De Ritis ratio had a significant prognostic value for OS and CSS in all subgroups.ConclusionsThe present study suggests that an elevated pretreatment De Ritis ratio is significantly correlated with worse survival in patients with RCC. The pretreatment De Ritis ratio may serve as a potential prognostic biomarker in patients with RCC, but further studies are warranted to support these results.
Highlights
Renal cell carcinoma (RCC) is a common malignant tumor in adults, and its incidence has been increasing over the past two decades [1]
Of the 323 initially identified articles through the search strategy, 141 studies remained after removing duplicates (93 publications) and irrelevant studies (89 publications)
Five studies focused on metastatic RCC [24, 26, 27, 30, 31]
Summary
Renal cell carcinoma (RCC) is a common malignant tumor in adults, and its incidence has been increasing over the past two decades [1]. In 2020, approximately 73,750 new RCC cases and 14,830 deaths were predicted in the United States [2]. Despite an increase in early detection of RCC, nearly 20% of patients already have local progression or metastasis disease at initial diagnosis [3]. Postoperative cancer recurrence occurs in 20%–40% of patients with localized RCC [4]. It is of great value to define the prognostic indicators of survival, metastasis, or recurrence in patients with RCC. We performed this study to explore the prognostic value of the pretreatment aspartate transaminase to alanine transaminase (De Ritis) ratio in patients with renal cell carcinoma (RCC)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
